Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 26

1.

Identification and characterization of small molecule inhibitors of the ubiquitin ligases Siah1/2 in melanoma and prostate cancer cells.

Feng Y, Sessions EH, Zhang F, Ban F, Placencio-Hickok V, Ma CT, Zeng FY, Pass I, Terry DB, Cadwell G, Bankston LA, Liddington RC, Chung TDY, Pinkerton AB, Sergienko E, Gleave M, Bhowmick NA, Jackson MR, Cherkasov A, Ronai ZA.

Cancer Lett. 2019 May 1;449:145-162. doi: 10.1016/j.canlet.2019.02.012. Epub 2019 Feb 14.

PMID:
30771432
2.

Greensboro College: A Model of UDL in the Curriculum.

Bodgan G, Pass I.

Stud Health Technol Inform. 2018;256:119-127.

PMID:
30371466
3.

Capzimin is a potent and specific inhibitor of proteasome isopeptidase Rpn11.

Li J, Yakushi T, Parlati F, Mackinnon AL, Perez C, Ma Y, Carter KP, Colayco S, Magnuson G, Brown B, Nguyen K, Vasile S, Suyama E, Smith LH, Sergienko E, Pinkerton AB, Chung TDY, Palmer AE, Pass I, Hess S, Cohen SM, Deshaies RJ.

Nat Chem Biol. 2017 May;13(5):486-493. doi: 10.1038/nchembio.2326. Epub 2017 Feb 28.

4.

Cell-Based High-Throughput Luciferase Reporter Gene Assays for Identifying and Profiling Chemical Modulators of Endoplasmic Reticulum Signaling Protein, IRE1.

Rong J, Pass I, Diaz PW, Ngo TA, Sauer M, Magnuson G, Zeng FY, Hassig CA, Jackson MR, Cosford ND, Matsuzawa S, Reed JC.

J Biomol Screen. 2015 Dec;20(10):1232-45. doi: 10.1177/1087057115600414. Epub 2015 Aug 11.

PMID:
26265713
5.

Small-molecule antagonists of Gli function.

Ardecky R, Magnuson GK, Zou J, Ganji SR, Brown B, Ngo T, Lee J, Zeng FY, Sun Q, Stonich D, Salaniwal S, Sakata T, Rack PG, Casabar JKT, Mangravita-Novo A, Smith LH, Sergienko E, Chung TDY, Pinkerton AB, Pass I, Chen JK.

Probe Reports from the NIH Molecular Libraries Program [Internet]. Bethesda (MD): National Center for Biotechnology Information (US); 2010-.
2012 Dec 17 [updated 2014 May 13].

6.

Selective UBC 13 Inhibitors.

Ardecky R, Madiraj C, Matsuzawa S, Zou J, Ganji S, Pass I, Ngo TA, Pinkerton AB, Sergienko E, Su Y, Stonich D, Mangravita-Novo A, Vicchiarelli M, McAnally D, Smith LH, Diwan J, Chung TDY, Matsuzawa Y, Wimer C, Diaz PW, Reed JC.

Probe Reports from the NIH Molecular Libraries Program [Internet]. Bethesda (MD): National Center for Biotechnology Information (US); 2010-.
2012 Apr 16 [updated 2014 May 13].

7.

Potent inhibitors of lipid droplet formation.

Zou J, Ganji S, Pass I, Ardecky R, Peddibhotla M, Loribelle M, Heynen-Genel S, Sauer M, Pass I, Vasile S, Suyama E, Malany S, Mangravita-Novo A, Vicchiarelli M, McAnally D, Cheltsov A, Derek S, Shi S, Su Y, Zeng FY, Pinkerton AB, Smith LH, Kim S, Ngyuen H, Zeng FY, Diwan J, Heisel AJ, Coleman R, McDonough PM, Chung TDY.

Probe Reports from the NIH Molecular Libraries Program [Internet]. Bethesda (MD): National Center for Biotechnology Information (US); 2010-.
2011 Oct 31 [updated 2014 May 13].

8.

Identification of a selective inhibitor of murine intestinal alkaline phosphatase (ML260) by concurrent ultra-high throughput screening against human and mouse isozymes.

Ardecky RJ, Bobkova EV, Kiffer-Moreira T, Brown B, Ganji S, Zou J, Pass I, Narisawa S, Iano FG, Rosenstein C, Cheltsov A, Rascon J, Hedrick M, Gasior C, Forster A, Shi S, Dahl R, Vasile S, Su Y, Sergienko E, Chung TDY, Kaunitz J, Hoylaerts MF, Pinkerton AB, Millán JL.

Bioorg Med Chem Lett. 2014 Feb 1;24(3):1000-1004. doi: 10.1016/j.bmcl.2013.12.043. Epub 2013 Dec 19.

9.

A Selective Murine Intestinal Alkaline Phosphatase (muIAP) Inhibitor.

Ganji S, Zou J, Brown B, Bobkova EV, Ardecky R, Rosenstein C, Pass I, Dahl R, Vasile S, Sergienko E, Shi S, Stonich D, Cheltov A, Su Y, Mangravita-Novo A, Vicchiarelli M, McAnally D, Kim S, Nguyen H, Moreira TK, Smith LH, Zeng FY, Diwan J, Chung TDY, Pinkerton AB, Kaunitz J, Millán JL.

Probe Reports from the NIH Molecular Libraries Program [Internet]. Bethesda (MD): National Center for Biotechnology Information (US); 2010-.
2011 Oct 31 [updated 2013 Mar 7].

10.

TR-FRET-based high-throughput screening assay for identification of UBC13 inhibitors.

Madiraju C, Welsh K, Cuddy MP, Godoi PH, Pass I, Ngo T, Vasile S, Sergienko EA, Diaz P, Matsuzawa S, Reed JC.

J Biomol Screen. 2012 Feb;17(2):163-76. doi: 10.1177/1087057111423417. Epub 2011 Oct 27.

11.

Tks5-dependent, nox-mediated generation of reactive oxygen species is necessary for invadopodia formation.

Diaz B, Shani G, Pass I, Anderson D, Quintavalle M, Courtneidge SA.

Sci Signal. 2009 Sep 15;2(88):ra53. doi: 10.1126/scisignal.2000368.

12.

Nck adaptor proteins link Tks5 to invadopodia actin regulation and ECM degradation.

Stylli SS, Stacey TT, Verhagen AM, Xu SS, Pass I, Courtneidge SA, Lock P.

J Cell Sci. 2009 Aug 1;122(Pt 15):2727-40. doi: 10.1242/jcs.046680. Epub 2009 Jul 13.

13.

The novel adaptor protein Tks4 (SH3PXD2B) is required for functional podosome formation.

Buschman MD, Bromann PA, Cejudo-Martin P, Wen F, Pass I, Courtneidge SA.

Mol Biol Cell. 2009 Mar;20(5):1302-11. doi: 10.1091/mbc.E08-09-0949. Epub 2009 Jan 14.

14.

A role for the podosome/invadopodia scaffold protein Tks5 in tumor growth in vivo.

Blouw B, Seals DF, Pass I, Diaz B, Courtneidge SA.

Eur J Cell Biol. 2008 Sep;87(8-9):555-67. doi: 10.1016/j.ejcb.2008.02.008. Epub 2008 Apr 15.

15.

The SRC substrate Tks5, podosomes (invadopodia), and cancer cell invasion.

Courtneidge SA, Azucena EF, Pass I, Seals DF, Tesfay L.

Cold Spring Harb Symp Quant Biol. 2005;70:167-71.

PMID:
16869750
16.

The adaptor protein Tks5/Fish is required for podosome formation and function, and for the protease-driven invasion of cancer cells.

Seals DF, Azucena EF Jr, Pass I, Tesfay L, Gordon R, Woodrow M, Resau JH, Courtneidge SA.

Cancer Cell. 2005 Feb;7(2):155-65.

17.

The adaptor protein fish associates with members of the ADAMs family and localizes to podosomes of Src-transformed cells.

Abram CL, Seals DF, Pass I, Salinsky D, Maurer L, Roth TM, Courtneidge SA.

J Biol Chem. 2003 May 9;278(19):16844-51. Epub 2003 Mar 3.

18.
19.

Antagonism of PI 3-kinase-dependent signalling pathways by the tumour suppressor protein, PTEN.

Downes CP, Bennett D, McConnachie G, Leslie NR, Pass I, MacPhee C, Patel L, Gray A.

Biochem Soc Trans. 2001 Nov;29(Pt 6):846-51. Review.

PMID:
11709086
20.

Targeting mutants of PTEN reveal distinct subsets of tumour suppressor functions.

Leslie NR, Bennett D, Gray A, Pass I, Hoang-Xuan K, Downes CP.

Biochem J. 2001 Jul 15;357(Pt 2):427-35.

21.

Tumor suppressor and anti-inflammatory actions of PPARgamma agonists are mediated via upregulation of PTEN.

Patel L, Pass I, Coxon P, Downes CP, Smith SA, Macphee CH.

Curr Biol. 2001 May 15;11(10):764-8.

23.

The lipid phosphatase activity of PTEN is critical for its tumor supressor function.

Myers MP, Pass I, Batty IH, Van der Kaay J, Stolarov JP, Hemmings BA, Wigler MH, Downes CP, Tonks NK.

Proc Natl Acad Sci U S A. 1998 Nov 10;95(23):13513-8.

25.

THE CONVERSION OF HEMATIN TO BILIRUBIN FOLLOWING INTRAVENOUS ADMINISTRATION IN HUMAN SUBJECTS.

Pass IJ, Schwartz S, Watson CJ.

J Clin Invest. 1945 May;24(3):283-91. No abstract available.

26.

Infarction of the Liver.

Pass IJ.

Am J Pathol. 1935 May;11(3):503-526.1. No abstract available.

Supplemental Content

Support Center